Recruiting
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors - CV202-103
Updated: 17 August, 2020 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Participants must have metastatic colorectal or pancreatic cancer - Eastern Cooperative Oncology Group (ECOG) performance status of ≤1 - Ability to swallow pills or capsules - All participants will be required to undergo mandatory pre and on-treatment biopsies - Adequate marrow function - Adequate other organ functions - Ability to comply with study visits, treatment, procedures, PK and PD sample collection, and required study follow-up Exclusion Criteria: - Histology other than adenocarcinoma (neuroendocrine or acinar cell) - Suspected, known, or progressive CNS metastases (Imaging required only if participants are symptomatic) - Participants with active, known or suspected autoimmune disease - Participants with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administration - Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity - Prior treatment with CCR2 and/or CCR5 inhibitors, PD-1, PD(L)-1 or CTLA-4 antibodies - History of allergy to study treatments or any of its components of the study arm that participant is enrolling Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information